Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth

International Journal of Radiation Oncology Biology Physics

Volumn 57, Issue 1, 2003, Pages 24-28

  Kaminski, Joseph M L ^a   Hanlon, Alexandra L ^a   Joon, Daryl Lim ^c   Meistrich, Marvin ^b   Hachem, Paul ^a   Pollack, Alan ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c NONE

Author keywords

Cancer; Hormones; Neoadjuvant; Prostate; Radiotherapy

Indexed keywords

BIOCHEMISTRY; IMPLANTS (SURGICAL); RADIOTHERAPY; TUMORS;

ANDROGEN DEPRIVATION (AD);

ONCOLOGY;

ANDROGEN; TESTOSTERONE;

ANALYTIC METHOD; ANDROGEN DEPRIVATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER THERAPY; CONTROLLED STUDY; HORMONE SUBSTITUTION; MALE; MULTIMODALITY CANCER THERAPY; NONHUMAN; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RAT; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 0042566204     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00539-X     Document Type: Article

References (16)

1. Zagars G.K., Pollack A., von Eschenbach A.C. Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation. Cancer. 80:1997;764-775.
2. Zietman A.L., Nakfoor B.M., Prince E.A., et al. The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor An in vitro and in vivo study . Cancer J Sci Am. 3:1997;31-36.
3. Granfors T., Tomic R., Bergh A., et al. After radiotherapy testosterone stimulation is unable to increase growth in the Dunning R3327-PAP prostate tumour. Urol Res. 27:1999;357-361.
4. Pollack A., Irvin G.L., Block N.L., et al. Hormone sensitivity of the R3327-G rat prostate adenocarcinoma Growth rate, DNA content, and hormone receptors . Cancer Res. 42:1982;2184-2190.
5. Pollack A., Block N.L., Stover B.J., et al. In vivo selection of androgen-insensitive cells in R3327-G rat prostate tumors Diethylstilbestrol diphosphate treatment versus orchiectomy . J Natl Cancer Inst. 70:1983;907-914.
6. Lawton C.A., Winter K., Murray K., et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 49:2001;937-946.
7. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 337:1997;295-300.
8. Granfors T., Modig H., Damber J.E., et al. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement A prospective randomized trial . J Urol. 159:1998;2030-2034.
9. Pilepich M.V., Winter K., John M.J., et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 50:2001;1243-1252.
10. Pollack A., Ashoori F., Sikes C., et al. The early supra-additive apoptotic response of R3327-G prostate tumors to androgen ablation and radiation is not sustained with multiple fractions. Int J Radiat Oncol Biol Phys. 46:2000;153-158.
11. Pollack A., Salem N., Ashoori F., et al. Lack of prostate cancer radiosensitization by androgen deprivation. Int J Radiat Oncol Biol Phys. 51:2001;1002-1007.
12. Hanlon A.L., Horwitz E.M., Hanks G.E., et al. Short term androgen deprivation and PSA doubling time Their relationship to one another and to disease progression following radiation therapy for prostate cancer . Int J Radiat Oncol Biol Phys. 54:(Suppl. 2):2002;136.
13. Hanlon A.L., Diratzouian H., Hanks G.E. Posttreatment prostate-specific antigen nadir is highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys. 53:2002;297-303.
14. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 281:1999;1591-1597.
15. D'Amico A.V., Cote K., Loffredo M., et al. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol. 20:2002;4567-4573.
16. Zagars G.K., Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol. 44:1997;213-221.